Overview / Abstract: |
Over the last several decades, advances in non-Hodgkin lymphoma (NHL) management have improved survival; however, relapse and the emergence of treatment-resistant NHL following standard therapy remain ongoing treatment challenges. With conventional therapy for B-cell NHL, response rates are suboptimal and many patients relapse, highlighting the need for novel treatments that address the risk of disease progression. Recently, several novel therapies—including small-molecule inhibitors of the B-cell receptor pathway and next-generation monoclonal antibody therapies—have emerged or advanced in clinical trials. These agents offer the potential to dramatically improve outcomes in some treatment-resistant patients. This activity has been developed to help advanced-practice oncology professionals stay current on the newest targeted NHL therapies and the best strategies for their effective use, particularly in the management of patients with multidrug-resistant and relapsing NHL. Additionally, this activity reviews current best practices for detecting variations in the natural history of NHL over time with the goal of improving long-term outcomes. |
Expiration |
Apr 08, 2020 |
Discipline(s) |
Nurse Practitioner , Physician CME, Physician Assistant CME |
Format |
Online |
Credits / Hours |
1 |
Accreditation |
ACCME, ACPE |
Presenters / Authors / Faculty |
Barbara Barnes Rogers, CRNP, MN, AOCN, ANP-BC |
Activity Specialities / Related Topics |
Hematology, Oncology / Cancer / Radiation Therapy |
Sponsors / Supporters / Grant Providers |
This activity is supported by an educational grant from Celgene Corporation, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. |
Keywords / Search Terms |
RedMedEd RedMedEd, Horizon CME, WSPA, free CME, NHL, non-Hodgkin lymphoma, B-cell, small-molecule inhibitors, b-cell receptor pathway, monoclonal antibody therapies, NHL therapies, treatment resistant NHL, CAR-T Free CE CME |